Zealand Pharma A/S · OMXCOP:ZEAL

Zealand Pharma A/S — Investor Day (2015)

14 slides from Zealand Pharma A/S's investor day presentation, 2015

  1. Slide 1: ZP1848 for the treatment of Short Bowel Syndrome

    ZP1848 for the treatment of Short Bowel Syndrome By Adam Steensberg, SVP and CMO Zealand Pharma A/S page 1

  2. Slide 2: What is Short Bowel Syndrome (SBS)?

    What is Short Bowel Syndrome (SBS)? A malabsorption disorder caused by the surgical removal of the Normal SBS intestine Massive surgical resections due to implications Length Length Crohn’s disease, ~8.5m/~25ft <2m/~6.5ft postoperative resection, embolism, thrombus, trauma, malignancy, complications

  3. Slide 3: Short Bowel Syndrome: Orphan disease with regional differences in prevalence

    Short Bowel Syndrome Orphan disease with regional differences in prevalence Estimated Point Prev. 19941,a Period Prev. 20102,a Regional differences due to differences in awareness and care Netherlands 2.4 14.7 Opportunity for improving Belgium care (prevalence has 2.2 8 increased in countries with D

  4. Slide 4: The life of an SBS patient - Long days and restless nights

    The life of an SBS patient - Long days and restless nights Patients are dependent on HPN support for 8-12 hours/day (3-7 days/week) Energy Eat/drink Level real food Parental Nutrition Desired Energy Level Start PN End PN Prepare PN Start PN 9 PM 3 AM 9 AM 3 PM 9 PM TIMELINE (hours) At night patients

  5. Slide 5: A day in the life of an SBS patient

    A day in the life of an SBS patient - Spontaneity and flexibility are severely limited “I was always a spontaneous person; but no more, every day is planned” I can never take “a day off my body” “If HPN time could somehow be concentrated…. that would be a blessing” Patient goals: less dependence on

  6. Slide 6: GLP-2 treatment - To improve imbalances of absorption and secretion

    GLP-2 treatment - To improve imbalances of absorption and secretion Healthy individuals SBS patients SBS patients on GLP-2 Intestinal absorption and secretion Reduced intestinal absorption therapy balanced capacity leading to fluid/nutrition Increase intestinal absorption of loss fluid and nutrients

  7. Slide 7: The biological actions of GLP-2 illustrate its therapeutic potential for SBS

    The biological actions of GLP-2 illustrate its therapeutic potential for SBS In the human body, GLP-2 GLP-2 is a peptide secreted after a meal1 The native peptide is REDUCED INCREASED INCREASED Gastric emptying2 Intestinal blood flow4 Nutrient and fluid degraded (inactivated) absorption6 by DPP-4, r

  8. Slide 8: A long-acting GLP-2 analogue

    ZP1848 - A long-acting GLP-2 analogue Zealand Pharma A/S page 8 page 8

  9. Slide 9: ZP1848 - a long-acting GLP-2 analogue for liquid formulation

    ZP1848 - a long-acting GLP-2 analogue for liquid formulation Parameter ZP18481 Teduglutide2 Structure 39-aa 33-aa ZP1848 increases small Half-life intestinal mass 14 -17 hours 1.3 - 2 hours (humans) ZP1848 GLP-2 analogue 125 (% increase over vehicle) Liquid, ready-to- Lyophilized, for Formulation us

  10. Slide 10: ZP1848 is safe and well tolerated - Phase I trial (healthy subjects)

    ZP1848 is safe and well tolerated - Phase I trial (healthy subjects) Double-blind, placebo-controlled, safety and tolerability study Phase Ia: Single dose1 Results Common adverse event’s o Mild/transient local reactions at highest ZP1848 dose No serious adverse events No overall difference in system

  11. Slide 11: ZP1848 is safe and well tolerated - Phase I trial (Crohn's disease)

    ZP1848 is safe and well tolerated - Phase I trial (Crohn’s disease, in remission) Double-blind, placebo-controlled, safety and tolerability study Phase Ib: Multiple dose1 86% increase in plasma citrulin Study Design following 2 weeks of dosing Placebo ZP1848 Plasma citrulline, % of baseline N = 10 2

  12. Slide 12: Planned outlook for ZP1848

    Planned outlook for ZP1848 Phase III enabling toxicology studies initiated Phase II CPoC dose-finding trial to be initiated Q1 2016 Device development expected to be initiated in 2016 Zealand Pharma A/S page 12

  13. Slide 13: Phase II trial in patients with SBS - Planned for initiation in Q1 2016

    Phase II trial in patients with SBS - Planned for initiation in Q1 2016 Double-blind Proof-of-Concept dose-finding trial CROSSOVER High Med/low Screening Wash Follow- and Medium High/low out up recruitment Low High/med T1 T2 T3 T4 -21 0 21 49 70 105 TIMELINE (days) N = 18 Primary endpoint Secondary

  14. Slide 14: ZP1848 has therapeutic potential for SBS

    ZP1848 has therapeutic potential for SBS Improved formulation, administration o Ready-to-use/pen device o Improved convenience Improved pharmacology profile o Increased half-life Increase functional capacity of remaining intestine o Improved absorptive capacity o Improved fluid balance Improve patie

Zealand Pharma — Investor Day (2015) on 6ix